Actionable Insights to Improve Care for Your Aortic Stenosis Patients

Rahul Sharma, MD, MBBS, FRACP
Assistant Professor of Medicine, Stanford University
Director of Structural Interventions, Stanford Health Care

We’re all familiar in clinical practice with many patients who, at least on first glance, look the same. If you look at the output of the echo report and database, two patients appear to fall under the moderate AS category but may have been undiagnosed with severe AS. The CardioCare platform applies predictive algorithms to determine which patient has a higher chance of having undiagnosed severe AS, enabling physicians to quickly prioritize these patients for a second review.

CardioCare is not intended for use in diagnosis, cure, mitigation, treatment or prevention of structural heart disease. Product intended for secondary clinical review.

Early data from the CardioCare platform’s algorithm show significant variability in the percentage of patients flagged at each participating site. There is opportunity to reduce variability in diagnoses everywhere, regardless of big destination referral centers or rural community hospitals.

By identifying patients sooner, we can quickly place our patients on the appropriate care pathway, leading to better outcomes and a happier, healthier patient. With such large patient populations, it can be a challenge for structural heart programs to manage severe patients, while providing proactive surveillance for moderate patients that progress at different rates. The CardioCare platform has made it easy for our team to prioritize our large patient population and provide life saving therapies before these patients become too sick to treat.

Watch my presentation below to learn more. 

#DigitalHealth #PrecisionMedicine #ArtificialIntelligenceSolutions

Related Articles

egnite Research

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.

Figure 1: Observed Mortality Stratified by GLP-1 RA and/or SGLT2i Prescription
egnite Research

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,

egnite Research

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.